| |
|
|
|
|
|
|
|||
|
AW Wognum, PM Lansdorp, AC Eaves and G Krystal
Terry Fox Laboratory, B.C. Cancer Research Centre, Vancouver, Canada.
We recently reported the development of several monoclonal antibodies
(MoAbs) to native human erythropoietin (Ep). In the present study we have
used the two antibodies with highest affinity to develop a two- sided or
sandwich enzyme-linked immunosorbent assay (ELISA) to measure Ep in human
serum. In this assay Ep is incubated in microtiter wells precoated with the
first (IgE) anti-Ep antibody. Assay wells are then incubated with the
second (IgG1) anti-Ep antibody, which is labeled noncovalently with the
enzyme alkaline phosphatase (AP) by means of bispecific tetrameric antibody
complexes consisting of IgG1 anti-Ep cross-linked to IgG1 anti-AP using rat
MoAbs specific for mouse IgG1. Application of this noncovalent labeling
procedure, in combination with substrate amplification, results in a
detection sensitivity of 0.5 to 1.0 mU/sample (5 to 10 mU/mL), which makes
this assay suitable for measuring normal serum Ep levels. The validity of
this ELISA for quantitating Ep in biological fluids was demonstrated by the
parallelism obtained between pure recombinant Ep dose-response curves and
those obtained with plasma and serum from healthy donors and patients with
various hematologic disorders. Normal plasma Ep levels detected with this
ELISA ranged from 9 to 101 mU/mL with a mean of 32 +/- 23 (SD) mU/mL. Ep
levels in sera from patients with polycythemia vera were in the low to
normal range, whereas Ep levels in sera from patients with secondary
polycythemia and patients with aplastic anemia were moderately to strongly
elevated. These results demonstrate that the Ep-ELISA is a sensitive,
reliable, and nonradioactive immunologic method for quantitating Ep levels
and should prove useful in a variety of clinical and laboratory settings.
This article has been cited by other articles:
| ||||||||||
| Copyright © 1989 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||